ENGLEWOOD, Colo., May 2 /PRNewswire/ -- Baxa Corporation announces the release of the new PhaSeal System Connector, which attaches a PhaSeal Injector to an IV line for safe administration of hazardous drugs. The new Luer Lock Connector was redesigned in response to customer requests for a closed system that can be used with needleless IV access devices. The new connector is longer, to accommodate valve-actuated access devices, while ensuring that the injector needle is never exposed.
The PhaSeal System is a set of disposable containment devices that connect the original drug vial, syringe and IV injection or infusion set together for a completely sealed drug pathway. The system’s double membrane provides dry connections between system components, preventing drug leakage. Because PhaSeal is a closed system, hazardous drugs are contained throughout the entire process of drug transfer, preparation, transport, administration and disposal. The new connector ensures that the PhaSeal System remains closed, even with unique valve-actuated IV line access devices.
“The PhaSeal System is the only documented, closed system for safe handling of antineoplastics and other hazardous drugs,” affirms Agneta Ekblad, RN, Vice President, Oncology Solutions for Baxa Corporation. Closed systems have been recommended by the National Institute for Occupational Safety and Health (NIOSH) and the Oncology Nurses Society to provide an engineering control against environmental and personal contamination. An Alert published by NIOSH in March 2004 details research describing the significant health risks related to handling, mixing and administering hazardous drugs. The document recommends a number of measures to reduce or eliminate human exposure to these toxic hazards in the workplace.
The new PhaSeal Connectors are currently in inventory, and replace the previously sold connectors. Products are available directly from Baxa Corporation and also through medical products wholesalers, under the original order numbers.
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com/.
About Carmel Pharma ab
The PhaSeal System is manufactured in Sweden by Carmel Pharma ab of Goteborg, Sweden. Introduced in Europe in 1994, the PhaSeal System is used in most Swedish hospitals, with its benefits documented by a significant body of scientific research on the health risks associated with the preparation and administration of cytotoxic drugs. The PhaSeal System is protected by a comprehensive patent portfolio in the U.S., European Union and Japan. For more information on Carmel Pharma, please visit http://www.carmelpharma.se/.
Contacts: Marian Robinson, Vice President, Marketing Baxa Corporation: 800-567-2292 ext. 2157 or 303-617-2157 Email: marian.robinson@baxa.com Maggie Chamberlin Holben, APR Absolutely Public Relations: 303-984-9801 or 303-669-3558 Email: maggie@absolutelypr.com
Baxa Corporation
CONTACT: Marian Robinson, Vice President, Marketing of Baxa Corporation,+1-800-567-2292 ext. 2157 or +1-303-617-2157, marian.robinson@baxa.com; orMaggie Chamberlin Holben, APR, Absolutely Public Relations, +1-303-984-9801 or+1-303-669-3558, maggie@absolutelypr.com, for Baxa Corporation
Web site: http://www.carmelpharma.se/
Web site: http://www.baxa.com/